Roche drug cocktail doubles chance of halting lung cancer
Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented.
0 comments:
Post a Comment